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1. Introduction
Fungal-derived natural products are a diverse class of
compounds with interesting structural features and bio-
logical activities that have allowed them to account for a
significant number of clinical therapeutics.[1] For this
reason, an increased effort has been placed on the isola-
tion of new members of this class of natural products, and
in screening these secondary metabolites for useful bio-
logical activities. The diverse class of prenylated indole al-
kaloids isolated from the Aspergillus and Penicillium
genera of fungi have received increasing levels of atten-
tion due to their interesting chemical architectures and
biological activities. Structurally, the paraherquamide,[2]
brevianamide,[3] stephacidin,[4] and notoamide[5] natural
products are unique in that many of them contain a
bicyclo[2.2.2]diazaoctane core structure (Scheme 1).
These families of alkaloids have attracted biomedical at-
tention and have been reported to display antitumor,[4] in-
secticidal,[6] antihelmintic,[2d] calmodulin-inhibititory,[7]
and antibacterial properties.[4] These intriguing structural
and biological properties have lead to a number of syn-
thetic endeavors towards this class of natural products.[8]
The pioneering work from Sammes[9] and Birch,[10]
along with more recent work from our laboratories,[11] has
shown that these natural products are derived from l-
tryptophan, a cyclic amino acid residue such as proline, b-
methylproline, or pipecolic acid, and one or two isoprene
units. Furthermore, the current experimental evidence
suggests that the bicyclo[2.2.2]diazaoctane ring system
arises from an intramolecular hetero Diels–Alder reac-
tion (IMDA) of an achiral 5-hydroxypyrazin-2(1 H)-
one.[11,12] Since all of the members of this family of natu-
ral products have been isolated in entiomerically pure
form, the putative biosynthetic IMDA reaction must pro-
ceed in a stereo- and enantio-controlled fashion, implying
that this cycloaddition is most likely enzyme-mediated.
Although enzyme-mediated Diels–Alder reactions have
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been proposed in the biosyntheses of a number of natural
products, the existence of a Diels–Alderase remains con-
troversial.[13] In providing corroborating support for this
biosynthetic proposal, we have shown that the IMDA is
an effective approach for the laboratory synthesis of the
bicyclo[2.2.2]diazaoctane core, and have applied this
methodology to the biomimetic syntheses of a number of
natural products.[14–18]
Since the isolation of (+)-stephacidin A ((+)-4) and B
(5) in 2002 by Bristol-Meyers-Squib from Aspergillus
James D. Sunderhaus graduated from
The Florida State University in 2002
with a B.S. in Chemistry and Biochem-
istry. He received his Ph.D. from the
University of Texas–Austin in 2009
under the supervision of Prof. Stephen
F. Martin. He is currently a postdoctor-
al fellow at Colorado State University
with Prof. Robert M. Williams, where
he works on the synthesis of intermedi-
David H. Sherman obtained his under-
graduate degree in Chemistry at the
University of California, Santa Cruz,
and completed his Ph.D. in the Depart-
ment of Chemistry at Columbia Univer-
sity with Professor Gilbert Stork. After
postdoctoral studies at the Yale Univer-
sity School of Medicine and MIT, Dr.
Sherman spent three years at Biogen
Research Corporation, and in 1987
moved to the John Innes Institute, Nor-
wich, England, to work with Professor
Sir David Hopwood in microbial genet-
ics. He began his academic career at the University of Minnesota in
1990, and in 2003 moved to the University of Michigan, Ann Arbor,
where he is the Hans W. Vahlteich Professor of Medicinal Chemis-
try.
Robert M. Williams recieved his B.A.
degree in Chemistry in 1975 from Syra-
cuse University. He obtained the Ph.D.
degree in 1979 at MIT (W. H. Rastetter)
and was a post-doctoral fellow at Har-
vard (1979–1980; R. B. Woodward/
Yoshito Kishi). He joined Colorado
State University in 1980 and was
named a University Distinguished Pro-
fessor in 2002. His interdisciplinary re-
search program at the chemistry–biol-
ogy interface is focused on the total
synthesis of biomedically significant
natural products, biosynthesis of secondary metabolites, studies on
antitumor drug–DNA interactions, HDAC inhibitors, amino acids,
and peptides.
Scheme 1. Representative prenylated alkaloids and their proposed biosynthesis.
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ochraceus,[4] our group has taken an interest in both the
synthesis[14,19] and biosynthesis of this secondary metabo-
lite. Our interest in the biosynthesis of 4 grew further
when Tsukamoto and co-workers isolated the structurally
related notamide natural products, as well as (+)-stepha-
cidin A and ()-versicolamide B (()-3), from a marine-
derived Aspergillus sp.[5] (Figure 1). Whereas the notoa-
mide alkaloids are of interest because they may provide
clues to the biogenesis of stephacidin A, the isolation of
versicolamide B was of particular interest due to its ste-
reochemical relationship to the other stephacidin and no-
toamide metabolites. The majority of the members of the
paraherquamides, stephacidins, and notoamides (i.e. , 2, 4,
and 6) have a bridgehead hydrogen (C6 in stephacidin A)
with a syn- relative configuration, while in versicolamide
B (C19 in versicolamide B) and the brevianamides (i.e. ,
1) the bridgehead hydrogen is in an anti- configuration.
This difference in the relative stereochemistry about the
bicyclo[2.2.2]diazaoctane core poses a number of fascinat-
ing questions relating to the biosynthesis of both 3 and 4.
Adding further intrigue to the biogenesis of the stepha-
cidins and notoamides is the fact that in 2006 the enantio-
mers of stephacidin A (()-4), notoamide B ((+)-6), and
versicolamide B ((+)-3) were isolated from the terrestrial
fungus Aspergillus versicolor.[20]
Although examples of antipodal natural products are
known to be produced by Nature, given the vast number
of naturally occurring secondary metabolites, examples of
this phenomena are exceedingly rare. In terms of the bio-
synthesis of 4, the isolation of the antipodal forms of ste-
phacidin A implies that the different species of Aspergil-
lus have evolved enantiomerically distinct genes for the
biosyntheses of the stephacidin and notoamide natural
products. Moreover, because the chirality of the bicyclo-
[2.2.2]diazaoctane core is believed to be formed from an
achiral aza-diene via the putative IMDA, the implication
is that the Aspergillus species may have evolved enantio-
merically distinct Diels–Alderases (Scheme 2). Thus, ste-
phacidin A would arise from an appropriate reverse-pre-
Scheme 2. The proposed biogenesis of both enantiomers of ste-
phacidin A.
Figure 1. Representative notoamide alkaloids and the enantiomeric forms of stephacin A, notoamide B, and versicolamide B.
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nylated cyclo-l-typtophan-l-proline, which would under-
go oxidation to give the achiral azadiene 18, which would
undergo an IMDA to give the two enantiomers of stepha-
cidin A in each specific species, respectively.
To answer these intriguing questions about the biosyn-
thesis of the stephacidins and notoamides, our research
group has embarked on a program to elucidate every
stage of their biosynthetic constructions. The goal of this
project is both to identify every intermediate in the bio-
synthesis, and to identify and assign function to every
gene in the notoamide gene cluster. To do this a number
of chemical and biochemical techniques have been uti-
lized, and our current efforts to determining the complete
biosynthetic pathway are summarized herein.
2. Investigations Into the Biosynthesis of the
Stephacidin and Notoamide Alkaloids
2.1. Originally Proposed Biosynthesis of Stephacidin A
In 2009, our laboratory had inadvertently synthesized a
prenylated indole alkaloid that would later be assigned
the name notoamide E (15). We provided an authentic
sample of this substance to the Tsukamoto laboratory
wherein this synthetic material was used to isolate and
identify this short-lived metabolite (notoamide E, 15)
from a marine-derived Aspergillus sp.[5b] This led to our
first proposed biogenesis of stephacidin A, which is out-
lined in Scheme 3. Starting from brevianamide F (19), re-
verse prenylation would give deoxybrevianamide E (20),
a known metabolite in stephacidin-producing organism-
s.[5a] Further prenylation and oxidation could then provide
notoamide E. Oxidation of 15 would provide the transi-
ent achiral azadiene (21), which could undergo the
IMDA cyclization to give stephacidin A. In order to de-
termine if notoamide E was indeed the precursor to 4 we
undertook the synthesis of both unlabeled 15 and doubly
13C-labeled 15 for use in biosynthetic incorporation stud-
ies.
The synthesis of notoamide E[21] started from 6-hydrox-
yindole, which was O-protected to give 23 (Scheme 4).
Subsequent chlorination and reverse prenylation follow-
ing conditions first reported by Danishefsky[22] provided
the C2-reverse-prenylated 26. The Boc-group was then
removed with TFA, and the resulting phenol was propar-
gylated to give 28 in good yield. Heating 28 in 1,2-dichlor-
obenzene resulted in the formation of the pyran ring.
Tryptophan 32 was then readily obtained via a three step
procedure involving formation of gramine 30, Somei-Ka-
metani[23] coupling with the glycine benzophenone imine
31, and subsequent hydrolysis. The free amine was then
Fmoc-protected, and Me3SnOH mediated hydrolysis of
the ethyl ester provided the racemic acid 33.
The acid 33 was then coupled with proline ethyl ester
to give a mixture of diasteriomeric dipetides 35. Treat-
ment of 35 with morpholine resulted in removal of the
Fmoc-group and subsequent cyclization to provide notoa-
mide E and epi-notoamide E in 40 % and 35% yields, re-
spectively. Thus, the total synthesis of notoamide E was
completed in 13 steps from commercially available 6-hy-
droxyindole. This route also provided access to doubly
13C-labeled notoamide E (37), which was synthesized for
use in biosynthetic incorporation studies.
2.1.2. Notoamide E Incorporation Studies
The synthetic doubly 13C-labeled 37 was incubated with
the marine derived Aspergillus sp., and the fungal ex-
tracts were analyzed for the presence of 13C-labeled me-
tabolites. If notoamide E was indeed the precursor to ste-
phacidin A, then the stephacidin A isolated from this ex-
periment should exhibit some level of 13C incorporation.
However, upon analyzing the fungal abstracts, the major
metabolites found containing 13C enrichment were notoa-
mides C, 3-epi-notoamide C, and notoamide D. To our
surprise, no 13C-labeled 3, 4, or 6 could be detected
(Scheme 5).[5b]
These results suggested that notoamide E is not the
precursor to stephacidin A, and that our originally pro-
posed biogenesis was incorrect. If notoamide E is not the
precursor to stephacidin A, and if the bicyclo-
[2.2.2]diazaoctane ring does indeed arise from an IMDA
reaction, then the order of steps in our original biosyn-
thetic proposal needed to be re-evaluated. One plausible
alternative envisioned that the formation of the bicyclo-
[2.2.2]diazaoctane core occurred before the formation of
the pyran ring. With this in mind, we set out to develop
and test a new biogenetic hypothesis.
Scheme 3. Originally proposed biosynthetic route to stephacidin A
via notamide E.
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2.2. Alternative Biogenesis of Stephacidin A
The formation of notoamide E from 20 requires three dis-
tinct steps, namely, an oxidation, a prenylation, and a
final oxidation/cyclization to form the pyran ring, with
the order of the initial oxidation and prenylation stages
being unknown. The IMDA could potentially occur
before each of these steps, which leads to a number of
biosynthetic possibilities that are outlined in Scheme 6.
Deoxybrevianamide E (20) can undergo either oxida-
tion to 41, or oxidation and IMDA cyclization to give 43.
If 20 undergoes an oxidation and IMDA reaction to give
43, then a straightforward oxidation/prenylation/cycliza-
tion (43!44!45!4) pathway would lead to stephacidin
A. However, if 20 undergoes oxidization to 41, two path-
ways to stephacidin A are possible. 6-Hydroxydeoxy-bre-
vianamide E (41) could be prenylated to give 42, which
must then undergo the IMDA to give 45. Alternatively,
41 could undergo the IMDA reaction to give hexacycle
44, which could then be prenylated to give 45. Addition-
ally, since the exact order of oxidation and prenylation
steps is unknown, it is possible that prenylation of 20 or
43 happens prior to the azadiene oxidation. Regardless of
the pathway, compound 45, which we have named notoa-
mide T, would be the last [stable] intermediate in the bio-
synthesis of stephacidin A.
In order to ascertain which of these pathways is opera-
ble in the biosynthesis of stephacidin A, we set out to
synthesize all of the remaining potential biosynthetic in-
termediates for use as authentic samples in identifying
hitherto unknown, trace or short-lived metabolites. We
additionally required that access to 13C-labeled isotopom-
ers of these substances for incorporation studies be readi-
ly adaptable from the synthetic routes. In addition to this,
we have initiated efforts into the genome-based charac-
terization of the producing Aspergillus sp. to help us fully
elucidate the biogenesis of the notoamide and stephacidin
alkaloids.
Scheme 5. Incorporation studies with doubly 13C-labeled notoa-
mide E.
Scheme 4. Synthesis of notoamide E.
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2.3. Syntheses of the Proposed Biosynthetic Intermediates to
Stephacidin A
2.3.1. Synthesis of 6-Hydroxydeoxybrevianamide E
In addition to being a potential intermediate in the bio-
synthesis of stephacidin A, 6-hydroxydeoxy-brevianamide
E is also believed to be the precusor to notoamide J, and
it was in this context that the synthesis of 41 was devel-
oped.[24] The synthesis of 41 began from the reverse pre-
nylated 6-hydroxyindole 26 and followed a route similar
to that described for the synthesis of notoamide E
(Scheme 7). Thus, indole 26 was converted to the corre-
sponding gramine derivative and reacted in a Somei–Ka-
metani coupling to provide tryptophan 46 in good yield.
Subsequent re-functionalization of the amino acid and
coupling with (S)-proline ethyl ester gave the dipeptide
47. The Boc-groups were then removed with TFA, and
the resultant crude amine was heated in toluene to pro-
vide 41 in 27 % yield along with an equal amount of the
trans-diketopiperazine (DKP).
2.3.2. Total Synthesis of Notoamide S
The synthesis of notoamide S[25] was initiated from the
propargylated indole 28, which was elaborated into tryp-
tophan 49 as previously described (Scheme 8). Trypto-
phan 49 was then coupled with N-Fmoc proline to give 50
in high yield. Subsequent Lindlars reduction and removal
of the Fmoc-group provided the free amine, which upon
heating in toluene underwent an aromatic Claisen rear-
rangement and cyclization to give 42 in 29 % yield over
the three steps. Thus, the synthesis of notoamide S was
completed in twelve steps from commercially available 6-
hydroxyindole.
Although at the outset of the synthesis the natural
origin of notoamide S was unknown, the authentic
sample was later used in helping to prove the existence of
42 as an intermediate in the biosynthesis of stephacidin
A. In addition, this route is currently being utilized for
the synthesis of double 13C-labeled notoamide S needed
for future incorporation studies.
2.3.3. Synthesis of Substrate 43
The simple hexacycle 43 represents the earliest possible
bicylo[2.2.2]diazaoctane-containing compound in the bio-
synthesis of stephacidin A. This substance (also named
ketopremalbranchiamide) was first synthesized in our lab-
oratory some twenty years ago,[26] and more recently hasScheme 7. The synthesis of 6-hydroxydeoxybrevianamide E (41).
Scheme 6. Potential biosynthetic pathways to stephacidin A.
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been employed as an intermediate in the synthesis of 13C-
labeled compounds that were utilized in the interrogation
of the biogenesis of the structurally related malbranchia-
mides.[27,28]
Our biomimetic synthesis[14b] of 43 began with the cou-
pling of the reverse-prenylated tryptophan 52[16a] with hy-
droxyproline 53 to give a diastereomeric mixture of di-
peptides 54 (Scheme 9). Subsequent removal of the Boc-
group and cyclization to the DKP provided 55. The reac-
tion of 55 under Mitsunobu conditions in warm CH2Cl2
provided the cycloadducts 43 and 56 in 46% and 21 %
yields, respectively, thus providing us with ample amounts
of 43 for further biological studies.
2.3.4. Synthesis of Substrate 44
The synthesis of substrate 44[29] was modeled after our
first reported biomimetic synthesis of stephacidin A.[14a]
Thus, the tryptophan 46 was re-functionalized and cou-
pled with hydroxyproline derivative 57 to give 58. Treat-
ment of 58 with Et3N in refluxing acetonitrile resulted in
cleavage of the Fmoc-group and cyclization to the diketo-
piperazine. Subsequent elimination of the alcohol moiety
in 59, and conversion of the resulting enamide to its
lactim ether provided 60. Upon treatment with aqueous
KOH, 60 underwent the desired isomerization and cycli-
zation to give a separable mixture of the syn- and anti-
products 61 and 62. Final hydrolysis of the lactim ether in
61 provided the desired substrate 44 (Scheme 10).
With the syntheses of 41, 42, 43, and 44 we have ac-
complished the synthesis of a majority of the potential
plausible intermediates for the biosynthesis of stephacidin
A. As seen in the next section, these authentic samples
proved crucial in determining the early steps of the bio-
synthetic pathway.
Scheme 9. The synthesis of substrate 43.Scheme 8. The total synthesis of notoamide S (42).
Scheme 10. The synthesis of substrate 44.
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2.4. Genome-Based Characterization of the Early Steps in the
Stephacidin A Biosynthesis
While we were in the process of synthesizing all of the
potential intermediates on the stephacidin A biosynthetic
pathway, we also undertook a genome-based characteri-
zation of the notoamide and stephacidin biosynthetic
pathways. To this end, the genome of the marine derived
Aspergillus sp. was sequenced and the notoamide (not)
gene cluster was identified (Figure 2).[29]
Bioinformatics analysis helped to predict the function
of the majority of the Not gene products, and this led to
the identification of two predicted aromatic prenyltrans-
ferases, NotC and NotF. These two prenyltransferases
would presumably catalyze the two key prenylation reac-
tions in the biosynthesis of stephacidin, and further analy-
sis of their function led to the elucidation of the early
stages of the pathway.
2.4.1. Identification of NotF as the Deoxybrevianamide E
Synthase
NotF was first identified as a prenyltransferase due to it
showing a high identity (40 %) to a putative dimethylallyl
tryptophan synthase (EER24759) found in Coccidioides
posadasii. The NotF gene was expressed in E. coli and
the purified enzyme was first tested with doubly 13C-la-
beled brevianamide F (63). The results of this experiment
revealed that NotF was effective in converting breviana-
mide F into deoxybrevianamide E (Scheme 11), thus con-
firming the role of NotF as a reverse prenyltransferase.
The substrate specificity was then tested by reacting
NotF with tryptophan, cyclo-(l-Phe-l-Pro), cyclo-(l-Trp-
l-Trp), and cyclo-(l-Trp-l-Tyr). In each of these exam-
ples, no prenylated products were detected. These indi-
cate that NotF shows selectivity for 19 and that the re-
verse prenylation must be an early step in the biosynthet-
ic pathway as initially assumed.
2.4.2. Identification of NotC as the Notamide S Synthase
The role of NotC as a prenyltransferase was also first pre-
dicted because of its sequence identity (50 %) to another
known prenyltransferase, FtmH in A. fumigatus.[30] To de-
termine the function of NotC, it was similarly expressed
in E. coli and the recombinant protein was isolated and
purified. The activity of NotC was then tested with four
putative substrates, 20, 41, 43, and 44. In the cases of 20,
43, and 44 no prenylated products could be detected.
However, when 41 was subjected to NotC, notoamide S
was cleanly produced, indicating that NotC catalyzes a
normal prenyltransferase at C7 of the indole ring
(Scheme 12). Similar to NotF, NotC is also highly sub-
strate-selective, and this specificity has allowed us to
identify the early stages of stephacidin biogenesis.
2.5. Revised Biogenesis of Stephacidin A
By combining the data garnered from our notoamide E
feeding studies with that obtained from our genomic char-
acterizations, we are able to propose a revised biogenesis
of stephacidin A and notoamide B (Scheme 13). Starting
from brevianaimde F (19), the NotF gene product cata-
lyzes the reverse-prenylation of brevianamide F, provid-
ing deoxybrevianamide E (20). Then, an as-of-yet uniden-
tified oxidase converts deoxybrevianamide E into 41,
which is prenylated in a normal sense by the NotC gene
product to give notoamide S (42). Notoamide S is then
presumed to be oxidized to the azadiene, which under-
goes the IMDA reaction to provide notoamide T (45).
Notoamide T would then be oxidized by another current-
ly unidentified oxidase that mediates fashioning of the
pyran ring to give stephacidin A. We have very recently
applied the same methodology used to prepare 43, 44,
and stephacidin A, to prepare notoamide T.[31] We are
currently conscripting this synthesis to prepare doubleScheme 11. Reaction of 13C-labeled brevianamide F with NotF.
Scheme 12. The prenylation of 6-hydroxydeoxybrevianamide E by
NotC.
Figure 2. The notoamide (not) biosynthetic gene cluster.
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13C-labeled notoamide T to validate its intermediacy as
the penultimate precursor to stephacidin A.
Further oxidation of 4 and subsequent Pinacol rear-
rangement would then provide notoamide B (6); a se-
quence that we have recently confirmed with synthetic,
double 13C-labeled stephacidin A.[32]
The identification and characterization of NotF and
NotC have allowed us to determine the timing of the two
prenylation steps in the biogenesis of stephacidin A and
to propose a revised biogenetic pathway. However, the
enzymes involved in a number of other steps are still un-
determined, and until these are identified, the exact bio-
synthesis of 4 remains speculative.
2.6. Proposed Biosynthesis of Versicolamide B
Based on the available experimental results, we are
tempted to suggest that there is a branch point in the bio-
synthetic pathway of stephacidin A that also accommo-
dates the construction of versicolamide B that we current-
ly suspect to be at the stage of notoamide S. As mention
previously, versicolamide B is unique among the stephaci-
din and notoamide natural products due to the anti- con-
figuration of the bridgehead hydrogen (C19) found in its
bicyclo[2.2.2]diazaoctane core. To account for the stereo-
chemical differences between 3 and 4, three possible bio-
synthetic pathways to versicolamide B have been pro-
posed, as outlined in Scheme 14.
In the first possible route to 3, notoamide S could un-
dergo two sequential oxidations to give notoamide C (13)
via 15. Notoamide C could then undergo oxidation to the
azadiene, possibly through the intermediacy of notoamide
M (16), and subsequent IMDA cyclization would give
()-versicolamide B. In order for this route to be viable,
the IMDA reaction has to occur to provide the required
anti stereochemistry at C19. Fortunately, both theoretical
calculations[33] and experimental results[18] have shown
that the IMDA reaction of an oxindole should proceed to
give the anti- product exclusively, lending support to this
biogenetic pathway. The presence of notoamide M (16)
among the naturally occur metabolites of Aspergillus
sp.[5d] lends support to this pathway, as 16 could be the
direct oxidation product of notoamide C, and the loss of
water from 16 could lead directly to the requisite aza-
diene. For the biosynthesis of the antipodal (+)-versicola-
mide B, 3-epi-notoamide C would presumably be the cor-
responding branch point as the absolute stereochemistry
at the spiro-oxindole stereogenic center would correlate
to that in (+)-versicolamide B.
A similar pathway can be envisioned where the IMDA
occurs prior to the formation of the pyran ring. In this
route 42 is first converted to the oxindole 65, which can
then undergo the IMDA reaction to give 66. Subsequent
cyclization to form the pyran ring would then provide ver-
sicolamide B. This pathway is analogous to the stephaci-
din A pathway in that the IMDA reaction occurs prior to
the formation of the pyran ring. However, to date there
has been no evidence suggesting the presence of 65 and/
or 66 in the fungal broth, and the previously mention
route seems more likely.
A third pathway involving the formation of 6-epi-ste-
phacidin A (68) is also possible. Thus, if the IMDA reac-
tion of the azadiene derived from 42 is not completely
diastereoselective, a mixture of notoamide T (45) and 6-
epi-notoamide T (67) would be produced. 6-epi-Notoa-
mide T could then be converted to 6-epi-stephacidin A,
which could be readily oxidized into 3.
However, since 6-epi-stephacidin A, or any other relat-
ed 6-epi-metabolites, have not been detected as natural
metabolites of any Aspergillus species to date, the likeli-
hood of this pathway being operable is greatly dimin-
ished. Although there is currently a high level of uncer-
tainty in the final steps of the versicolamide B biosynthe-
sis, future work with incorporation studies and characteri-
Scheme 13. The revised biosynthesis of stephacidin A.
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zation of the other Not enzymes should allow for a com-
plete, high-resolution elucidation of the entire biosynthet-
ic pathway.
3. Outlook
The identification and characterization of the NotF and
NotC enzymes from a marine-derived Aspergillus sp.
have allowed us to determine the timing of the two pre-
nylation steps in the biogenesis of stephacidin A, and to
propose a revised biogenetic pathway. However, the en-
zymes involved in a number of other steps are still unde-
termined, and until these are identified, the exact path-
way remains uncertain. To this end, efforts are ongoing to
identify the remaining genes involved in the pathway and
parallel efforts in the genomic mining of Aspergillus versi-
color, which produces the antipodal natural products, ste-
phacidin A, notoamide B, and versicolamide B, are being
actively investigated. We have also undertaken the syn-
theses of 13C-labeled notoamides S and T, to aid in deter-
mining if 45 is truly the final precursor to both (+)- and
()-stephacidin A.
This program has relied heavily on a robust technical
platform we have built over the past two decades, to ach-
ieve the chemical synthesis of virtually every conceivable
substrate and product for every stage of the biosynthetic
pathways to these prenylated indole alkaloids. The dis-
covery that Nature produces some of these metabolites in
antipodal forms (and optically pure), has greatly added to
the intrigue associated with how Nature fashions such
beautiful structures. The technical advances in genome se-
quencing technology, proteomics, and genomics, have pro-
vided us with the powerful tools necessary to fully under-
stand the fascinating biogenesis of these natural substan-
ces. We are at a very exciting stage of this work and look
forward to the discoveries that lie ahead.
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